Immutep to Present at February Investor Conferences

Rhea-AI Summary

Immutep (ASX: IMM; NASDAQ: IMMP) has announced participation in two key investor conferences in February 2022. CEO Marc Voigt will present at the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, followed by a Q&A session on February 18 at 3:40 PM ET. Additionally, Immutep will be at the 2022 BIO CEO & Investor Conference from February 14-17. The company's focus is on developing immunotherapy treatments for cancer and autoimmune diseases, primarily through its lead candidate, eftilagimod alpha.

SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled to take place in February 2022.

11th Annual SVB Leerink Global Healthcare Conference - Virtual
Event Dates:                 February 14 – 18, 2022
1-on-1 Meetings:           Management will be available for 1-on-1 meetings with institutional investors. Investors interested in scheduling a meeting should contact their SVB Leerink representative.
Event Details:                www.svbleerink.com/events/

During this virtual conference, Mr. Voigt is scheduled to provide a Company presentation followed by a Q&A session at 3:40 PM ET on Friday, February 18th. A live webcast of this event, as well as an archived recording, will be available at https://wsw.com/webcast/svbleerink67/immp/2662950.

2022 BIO CEO & Investor Conference: Hybrid Event
Event Dates:                 February 14 – 17, 2022
1-on-1 Meetings:           Management will be available for 1-on-1 meetings with institutional investors. Investors interested in scheduling a meeting should contact their BIO CEO representative.
Event Details:                www.bio.org/events/bio-ceo-investor-conference

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

 

 

 

FAQ

What importance does Immutep's participation in the February 2022 investor conferences hold for IMMP investors?

Immutep's participation in these conferences provides investors with insights into the company's strategies, progress on LAG-3 immunotherapy treatments, and opportunities for direct engagement with management.

When will Immutep's CEO present at the SVB Leerink Global Healthcare Conference?

Marc Voigt, CEO of Immutep, is scheduled to present on February 18, 2022, at 3:40 PM ET.

What is Immutep's lead product candidate mentioned in the press release?

The lead product candidate is eftilagimod alpha (efti or IMP321), which is designed to activate antigen presenting cells in cancer and infectious disease.

What is the significance of LAG-3 for Immutep's product development?

LAG-3 is a target for immunotherapy, and Immutep is developing several related therapies for cancer and autoimmune diseases, positioning the company as a leader in this innovative field.

How can investors schedule 1-on-1 meetings with Immutep's management during the conferences?

Investors can schedule 1-on-1 meetings by contacting their respective conference representatives at SVB Leerink or BIO CEO.